- What’s New? A new drug, Lecanemab (brand name: Leqembi), has shown promise in treating early-stage Alzheimer’s by targeting and removing amyloid plaques in the brain. Clinical trials have shown that it can slow the disease’s progress.
- Why It’s Important: This could be the first drug to truly slow down Alzheimer’s, offering hope to those in the early stages of the disease.
A New Drug That Targets Amyloid Plaques (2023-2024)
A New Drug That Targets Amyloid Plaques (2023-2024)
Simple Takeaway:
A new drug is helping slow Alzheimer’s by targeting the plaques in the brain that cause memory problems.